

RECEIPT OF R&D TAX INCENTIVE PAYMENT

Melbourne, Australia – 12 February 2024: Percheron Therapeutics Limited, an international biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce that it has received from the Australian Taxation Office an R&D Tax Incentive refund payment of \$1,576,657 for the 30 June 2023 financial year. The amount received was in relation to the expenditure incurred on eligible R&D activities undertaken in Australia and overseas.

“These funds will be applied directly to our ongoing international phase IIb clinical trial of ATL1102 in Duchenne muscular dystrophy,” commented Antisense CEO, Dr James Garner. “The study continues to progress well, and we anticipate data in the second half of calendar 2024.”

~ ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The Company’s lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The drug has previously reported promising results from an exploratory phase IIa study in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.
